Maxim Group analyst Naz Rahman has reiterated their bullish stance on VKTX stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Naz Rahman has given his Buy rating due to a combination of factors surrounding Viking Therapeutics’ promising developments in their clinical-stage therapies. The recent data from the Phase 2 VENTURE study highlights the effectiveness of VK2735, a dual-incretin receptor agonist, in significantly reducing cardiometabolic risks. This advancement not only supports the clinical value of VK2735 but also positions it as a competitive asset in the GLP-1 and obesity treatment space, potentially enhancing its marketability and reimbursement prospects.
Furthermore, Viking’s comprehensive approach, including both oral and injectable formulations, is expected to enhance their commercial competitiveness. The company’s plans to engage with the FDA to discuss the next steps for VK2735 further underscore their commitment to advancing this promising therapy. With the potential to address a range of metabolic diseases, VK2735’s development is seen as a significant step forward, justifying the Buy rating as Viking continues to advance its therapeutic offerings.
Rahman covers the Healthcare sector, focusing on stocks such as Silexion Therapeutics, Kazia Therapeutics, and Vivani Medical. According to TipRanks, Rahman has an average return of -9.3% and a 33.33% success rate on recommended stocks.